Evidence map›Paper›PMID 26921328›Full record

SynthesisCancer research2016

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Ruth C Travis, Paul N Appleby, Richard M Martin, Jeff M P Holly, Demetrius Albanes, Amanda Black, H B As Bueno-de-Mesquita, June M Chan, Chu Chen, Maria-Dolores Chirlaque and 41 more

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 4 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 4 syntheses or guidelines pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Current understanding and perspectives on growth and long-acting GH therapy in Japan.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2025
    Review
  16. Insulin-related traits and prostate cancer: A Mendelian randomization study.Computational and structural biotechnology journal · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors at 20 institutions in 13 countries.

Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Paul N ApplebyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Richard M MartinSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Jeff M P HollySchool of Clinical Science, Faculty of Medicine, University of Bristol, Bristol, UK.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
Amanda BlackDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
H B As Bueno-de-MesquitaDt. for Determinants of Chronic Diseases, National Institute for Public Health and the Environment (RIVM), Bilthoven, and Dt. of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands, and Dt. of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
June M ChanDepartments of Epidemiology & Biostatistics and Urology, University of California San Francisco, CA, USA.
Chu ChenDivision of Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Maria-Dolores ChirlaqueDepartment of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, and CIBER Epidemiología y Salud Pública, Spain.
Michael B CookDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
Mélanie DeschasauxSorbonne Paris Cité Epidemiology and Biostatistics Research Center, Nutritional Epidemiology Research Team, Inserm U1153, Inra U1125, Cnam, University Paris 13, University Paris 5, University Paris 7, F-93017, Bobigny, France.
Jenny L DonovanSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Luigi FerrucciIntramural Research Program, National Institute on Aging, Baltimore, MD, USA.
Pilar GalanSorbonne Paris Cité Epidemiology and Biostatistics Research Center, Nutritional Epidemiology Research Team, Inserm U1153, Inra U1125, Cnam, University Paris 13, University Paris 5, University Paris 7, F-93017, Bobigny, France.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia.
Edward L GiovannucciDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Marc J GunterDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Laurel A HabelDivision of Research, Kaiser Permanente, Northern California, Oakland, California, USA.
Freddie C HamdyNuffield Department of Surgery, University of Oxford, UK.
Kathy J HelzlsouerThe Prevention and Research Center, Mercy Medical Center, Baltimore, MD, USA.
Serge HercbergSorbonne Paris Cité Epidemiology and Biostatistics Research Center, Nutritional Epidemiology Research Team, Inserm U1153, Inra U1125, Cnam, University Paris 13, University Paris 5, University Paris 7, F-93017, Bobigny, France.
Robert N HooverDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
Joseph A M J L JanssenErasmus MC, Dept Internal Medicine, Rotterdam, the Netherlands.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
Tatsuhiko KuboUniversity of Occupational and Environmental Health, Kitakyushu, Japan.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, HI, USA.
E Jeffrey MetterIntramural Research Program, National Institute on Aging, Baltimore, MD, USA.
Kazuya MikamiKyoto Prefectural University of Medicine, Kyoto, Japan.
Joan K MorrisWolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, UK.
David E NealDepartment of Oncology, University of Cambridge, UK.
Marian L NeuhouserDivision of Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kotaro OzasaRadiation Effects Research Foundation, Hiroshima, Japan.
Domenico PalliMolecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy.
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Michael PollakDepartments of Medicine and Oncology, McGill University, Montreal, QC, Canada.
Alison J PriceCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Monique J RoobolErasmus MC, Dept of Urology Rotterdam, the Netherlands.
Catherine SchaeferDivision of Research, Kaiser Permanente, Northern California, Oakland, California, USA.
Jeannette M SchenkCancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gianluca SeveriCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia.
Meir J StampferDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Pär StattinDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Akiko TamakoshiHokkaido University Graduate School of Medicine, Sapporo, Japan.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, and Department of Biostatistics, University of Washington, Seattle, WA, USA.
Mathilde TouvierSorbonne Paris Cité Epidemiology and Biostatistics Research Center, Nutritional Epidemiology Research Team, Inserm U1153, Inra U1125, Cnam, University Paris 13, University Paris 5, University Paris 7, F-93017, Bobigny, France.
Nicholas J WaldDepartment of Oncology, University of Cambridge, UK.
Noel S WeissHuman Genetics Foundation, Torino, Italy.
Regina G ZieglerDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
Timothy J Key *Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Naomi E Allen *Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Cancer Genetics (United States) · USUniversity of Oxford · GBDélégation Paris 5 · FRUniversity of Washington · USErasmus MC · NLFred Hutch Cancer Center · USKaiser Permanente · USQueen Mary University of London · GBThe University of Melbourne · AUUniversity of Bristol · GBBrigham and Women's Hospital · USBristol City Council · GBCancer Center of Hawaii · USDaido University · JPGerman Cancer Research Center · DEImperial College London · GBInstitute on Aging · USInstituto Murciano de Investigación Biosanitaria · ESJohns Hopkins University · USKyoto Prefectural University · JP

Funding

SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
Multiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2M
VALIDATION OF A DIET HISTORY METHOD FOR EPIDEMIOLOGIC STUDIES OF CANCERP01CA033619 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1985 to 2010
$18.5M
Oxidative Damage and DNA Repair in the PCPTP01CA108964 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, IAN M · 2005 to 2009
$13.6M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
Energy Balance-Related Hormones & Prostate Cancer Incidence & ProgressionR01CA133891 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI GIOVANNUCCI, EDWARD · 2008 to 2012
$3.3M
The Hallmarks of Aging: Assessing accumulation of DNA lesions with age using single cell DNA sequencing in GESTALTZIAAG000358 · NIA · NATIONAL INSTITUTE ON AGING · PI FERRUCCI, LUIGI · 2017 to 2025
$253k
Cancer Research UK 16491Cancer Research UK 19170Cancer Research UK A19169NCI NIH HHS P01 CA033619NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA108964NCI NIH HHS R01 CA133891NCI NIH HHS R37 CA054281NCI NIH HHS U01 CA164973NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883
6 · The paper itself

Abstract

The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. After mutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300. ©2016 AACR.

Indexed as

AgedHumansInsulin-Like Growth Factor IMaleMiddle AgedProstatic NeoplasmsRisk FactorsInsulin-Like Growth Factor I

Identifiers

PMID26921328
PMCPMC4873385
OpenAlexW2274299408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.